Vascular biology of thrombosis: The role of platelet-vessel wall adhesion

Neurology

Volumn 57, Issue 5 SUPPL. 2, 2001, Pages

  Fitzgerald, D J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; THROMBIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL OCCLUSION; BLOOD VESSEL WALL; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0035845602     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.57.suppl_2.s1     Document Type: Article

References (27)

1. Atherosclerosis - An inflammatory disease
2. Atherosclerosis
3. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype
4. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death
5. Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque
6. Platelet activation in unstable coronary disease
7. Membrane-bound enzyme complexes in blood coagulation
8. Activation of the GP IIb-IIIa complex induced by platelet adhesion to collagen is mediated by both alpha2beta1 integrin and GP VI
9. Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha IIb beta 3 activation both in platelets and a transfected Chinese hamster ovary cell system
10. Extended-release dipyridamole/aspirin
11. Dipyridamole trials in stroke prevention
12. The regulation of vascular function by P2 receptors: Multiple sites and multiple receptors
13. Ticlopidine and clopidogrel
14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
15. Thrombin signalling and protease-activated receptors
16. Signaling through platelet integrin alpha IIb beta 3: Inside-out, outside-in, and sideways
17. On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor
18. Binding of recombinant fibrinogen mutants to platelets
19. Platelet GPIIb-IIIa blockers
20. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
21. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
22. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
23. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists
24. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis
25. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIb beta3) inhibitors
26. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
27. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: Evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis